Hello!
To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.
Brief
"On "14/02/2025", the "Medicines and Healthcare products Regulatory Agency (MHRA)" issued an update regarding "Efanesoctocog alfa approved to prevent and treat bleeding in children and adults with severe or moderate haemophilia A". Efanesoctocog alfa, also known as Altuvoct, is administered via intravenous injection and has shown effectiveness in reducing episodes of bleeding in patients aged 2 years and above. This approval aims to improve treatment options for individuals with haemophilia A."
Highlights content goes here...
Hello!
To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested
